Diallyllysergamide
Chemical compound
From Wikipedia, the free encyclopedia
N,N-Diallyllysergamide (DAL), also known as lysergic acid diallylamide (LDA), is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1][2] It is taken orally.[1]
- None
 | |
 | |
| Clinical data | |
|---|---|
| Other names | DAL; Lysergic acid diallylamide; LDA; d-Lysergic acid diallylamide; d-Diallyllysergamide |
| Routes of administration | Oral[1] |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.163.206 |
| Chemical and physical data | |
| Formula | C22H25N3O |
| Molar mass | 347.462 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Use and effects
In his 1997 book TiHKAL (Tryptamines I Have Known and Loved), Alexander Shulgin described DAL as producing "at best a touch of sparkle" of LSD at dose of 600 μg of the tartrate salt taken orally, but as also producing a sedation.[1] Subsequently, in a 2003 literature review, Shulgin listed an active dose as greater than 1 mg.[3] He has described the drug as being at least an order of magnitude less potent than LSD.[1][3]
Interactions
Pharmacology
Pharmacodynamics
DAL interacts with serotonin receptors, including the serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors.[2] It acts as a serotonin 5-HT2A receptor agonist, but with about 5-fold lower potency than LSD.[2]